Health AI Central
Share:
Peer-Reviewed Publication
Mol Ther Nucleic Acids2026;37(1):102844.March 12, 2026Journal Article

microRNA-422a promotes HIV replication and innate immune evasion by targeting MECP2.

Li Du1,2, Jean-Noël Billaud3, Sushama Telwatte4,5, Nikhila Kadiyala4,5, Prerna Dabral1,2, Mohamed S Bouzidi1,2, John Guatelli6,7, Steven A Yukl4,5, Satish K Pillai1,2
1Vitalant Research Institute, San Francisco, CA 94105, USA.
2Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
3DNAnexus, 1975 W EI Camino Real, Mountain View, CA 94040, USA.
4Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
5Veterans Affairs (VA) Medical Center, San Francisco, CA 94121, USA.
6Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
7VA San Diego Healthcare System, San Diego, CA 92161, USA.
PubMed PMC DOI PDF

Abstract

Understanding the mechanisms underlying interferon-alpha (IFNα) anti-human immunodeficiency virus type I (HIV-1) effects and HIV-1 innate immune evasion is critical to developing improved antiviral strategies. We previously reported that the microRNA (miRNA) miR-422a was the sole miRNA downregulated by IFNα treatment in vivo in people living with HIV (PLWH), and the extent of miR-422a reduction wa…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.